LGND
LIGAND PHARMACEUTICALS INC
LIGAND PHARMACEUTICALS INC (LGND) has 13 SEC Form 4 filings (40 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Jul 6, 2026.
The most active filer is Director KOZARICH JOHN W with 3 filings. Insiders have net sold $3.8M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Todd C. Davis
- Employees:68
- HQ:Jupiter, CA, US
- IPO:1992-11-18
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.8M
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Market Cap
$5.9B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| CLO & Secretary | Sale | 5,000 | $1.6M | Jul 6 | SEC ↗ | |
Sabba Stephen LFirst filing | Director | Sale | 2,145 | $545K | Jun 18 | SEC ↗ |
KOZARICH JOHN WFirst filing | Director | Sale | 467 | $108K | May 15 | SEC ↗ |
KOZARICH JOHN WFirst filing | Director | Sale | 459 | $103K | May 15 | SEC ↗ |
KOZARICH JOHN WFirst filing | Director | Sale | 1,575 | $352K | May 15 | SEC ↗ |
Reardon AndrewFirst filing | CLO & Secretary | Sale | 5,000 | $1.2M | May 5 | SEC ↗ |
Congress trading LGND
See timeline →- DRep. Gilbert CisnerosPurchase$1,001 - $15,0002026-05-29
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Related companies
LIGAND PHARMACEUTICALS INC is in the Healthcare sector.